"..apy, the agency said Wednesday in a statement. Opdivo was tested in 135 patients who lived, on average, 3.2 months longer than 137 who received the chemotherapy docetaxel, the FDA said. “ The FDA worked proactively with the company to facilitate the early submission and review of this important clinical trial when results first became available in late December 2014,”